<DOC>
	<DOC>NCT00209131</DOC>
	<brief_summary>The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining if the medication Flomax will result in improved stone passage rates following SWL.</brief_summary>
	<brief_title>Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy</brief_title>
	<detailed_description>Placebo blinded study examining the effects of Flomax on stone passage rates following SWL.</detailed_description>
	<mesh_term>Urolithiasis</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Patients 18 years old and above with urolithiasis scheduled for shock wave lithotripsy. Contraindications to Flomax Patients with renal impairment (serum creatinine above 2.0) Patients with hepatic impairment (liver enzymes 2.5 times the upper limit of normal) Use of other oral alpha blockers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>urolithiasis</keyword>
</DOC>